castle biosciences stock zacks

This compares to loss of 008 per. Castle Biosciences Inc.

Post Ipo Review Castle Biosciences Grows Despite Pandemic S Effects Ipos On Thestreet U S Ipo Research Opinion

Is a commercial-stage dermatological cancer company.

. The Zacks Scorecard is a complimentary set of indicators to use alongside the Zacks Rank. The Zacks Scorecard is a complimentary set of indicators to use alongside the Zacks Rank. Zacks proprietary data indicates that Castle Biosciences Inc.

This compares to loss of 008 per. It allows the investor to better focus on the stocks that are the best fit for his or. Castle Biosciences Inc.

It is focused on providing physicians and patients clinically actionable. It allows the investor to better focus on the stocks that are the best fit for his or her personal. CSTL came out with a quarterly loss of 080 per share versus the Zacks Consensus Estimate of a loss of 067.

Castle Biosciences Inc. According to Zacks Castle Biosciences Inc. Will beat the consensus EPS estimate.

Is currently rated as a Zacks Rank 3 and we are expecting an inline return from the CSTL shares relative to the. CSTL came out with a quarterly loss of 034 per share versus the Zacks Consensus Estimate of a loss of 029. So this combination makes it difficult to conclusively predict that Castle Biosciences Inc.

CSTL came out with a quarterly loss of 034 per share versus the Zacks Consensus Estimate of a loss of 029. On the other hand the stock currently carries a Zacks Rank of 3. This compares to loss of 017 per.

Castle Biosciences Inc Cstl Stock Price Quote News Stock Analysis